Cigna to remove AbbVie’s Humira from some drug reimbursement lists next year
By Patrick Wingrove (Reuters) – Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead. Cigna said Boehringer Ingelheim’s Cyltezo, Simlandi from Teva and Alvotech, and an unbranded version of Hyrimoz from Sandoz will be covered on some lists that are managed by its pharmacy […]